• Home
  • About Us
    • AdAlta at a glance
    • Board
    • Management Team
  • Technology
    • i-bodies
    • The i-body platform
    • Scientific Publications
  • Pipeline
    • The Growing AdAlta Pipeline
    • Fibrosis
    • CAR-T cancer therapeutics
  • Investors
    • Annual and Financial Reports
    • Presentations
    • Analyst Reports
    • ASX Announcements
    • News & Media
    • Corporate Governance
  • Contact Us

..Tag: job

AdAlta seeking Head of Drug Discovery

May 22, 2018

AdAlta is expanding its scientific team with the appointment of a Head of Drug Discovery that will be integral in using the powerful, next-generation antibody platform to develop a growing pipeline of i-bodies to move into clinical development.

For more information on the role, click here.

Archives

2016 News

  • Initial Director’s Interest Notice
  • AdAlta Extends Board with Appointment of US-Based Non Executive Director
  • Director Appointment
  • Results of AdAlta AGM 2016
  • AGM Presentation

2015 News

  • AdAlta and The University of Melbourne to develop i-bodies for the treatment of various eye diseases
  • Japanese patent granted for AdAlta i-body technology
  • AdAlta appoints Dr Paul MacLeman Chairman
  • AdAlta expands its scientific advisory team

2014 News

  • AdAlta expands its scientific advisory team
  • Lonza and AdAlta Announce a Strain Development Contract for Novel Biologic Therapeutics

2013 News

  • AdAlta collaborates with Crossbeta to find i-body for Alzheimer’s disease
  • AdAlta awarded voucher to explore benefits of technologies with Ferring Research Institute

2012 News

  • AdAlta and Baker IDI sign agreement to identify i-bodies to anti-thrombotic target
  • AdAlta and Roche sign agreement to evaluate shark antibody technology

2011 News

  • US patent granted for AdAlta i-body technology
  • AdAlta receives VC investment from Perth-based Yuuwa Capital

© 2025 AdAlta Limited Disclaimer | Privacy Policy
© 2016 AdAlta Limited